310 Mira Street, Stavropol, Russia, 355017
+7 8652 352524; +7 8652 353229.
+7 8652 352524.
The journal is included into The list of leading scientific periodicals.
53 patients with chronic hepatitis C were treated in multicenter clinical trial: 26 female and 27 male, 23 have received antiviral therapy in a past. Inclusion criteria were follows: ALT activity ≥1.5 ULN, absence of signs of liver cirrhosis decompensation and hepatocellular cancer. Bicyclol® medicine (Beijing Union Pharmaceutical Factory, PRC) was administered in a daily dose 150 mg during 12 weeks. A primary efficacy criterion was ALT activity. There were decrease in ALT, AST activity and bilirubin level in patients who received Bicyclol®, enhance in asthenic-vegetative syndrome as well. In the placebo group there weremultino such dynamics observed. Undesirable effects (UE) have been registered in 12 patients and appeared as a clinically negligible deviations in laboratory tests and were resulted from course of the main disease. In conclusions, Bicyclol® medicine has demonstrated efficacy in decrease of ALT activity, however no such effect was in placebo group. Tested medicine Bicyclol® is characterized with favorable safety profile and good tolerability. Bicyclol® use is reasonable in patients with active CHC with contraindications to antiviral treatment or after its fail.
1. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatitis C virus infection J. Hepatol. 2014;60:392–420.
2. Ferenci P., Bernstein D., Lalezari J. et al. ABT-450/rombitasvir and dasabuvir with or without ribavirin for HCV. N. Engl. J. Med. 2014;370:1983–1992.
3. Han Y., Shi J.-P., Ma A.-L. et al. Randomized, vitamin E controlled trial of Bicyclol plus metformin in non-alcoholic fatty liver disease patients with impaired fasting glucose. Clin. Drug Investig. 2014;34(1):1-7.
4. Liu G. T. Bicyclol: a novel drug for treating chronic viral hepatitis B and C. Med. Chem. 2009;5(1):29–43.
5. Liu G. T., Li Y., Wei H. L. et al. Mechanism of protective action of bicyclol against CCl-induced liver injury in mice. Liver Int. 2005;25(4):872–879.
6. Manns M. Marcellin P., Poordad F. et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414–426.
7. Pan S. Y. Dong H., Yu Z. L. et al. Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice. J. Pharm. Pharmacol. 2007;59(12):1657–1662.
8. Smets E. M. Garssen B., Bonke B., De Haes J. C. The Multidimensional Fatigue Inventory (MFI) psychometric qualities of an instrument to assess fatigue. Psychosom. Res. 1995;39(3):315–325.
9. Su H. L., Zhu Y. X., Gao Z. J. et al. Efficacy comparison between bicyclol and polyene phosphatidylcholine treatments for the patients with nonalcoholic fatty liver disease. Chin. J. Hepatol. 2011;19(7):552–553.
10. Sulkowski M. S. Gardiner D. F., Rodriguez-Torres M. et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection N. Engl. J. Med. 2014;370:211–221.
11. Wang H., Li Y. Protective effect of bicyclol on acute hepatic failure induced by lipopolysaccharide and D-galactosamine in mice. Eur. J. Pharmacol. 2006;53(1–3):194–201.
12. Xie W. A., Shi G., Zhang H. et al. randomized, multi central, controlled study of patients with hepatitis B e antigen-positive chronic hepatitis B treated by adefovir dipivoxil or adefovir dipivoxil plus bicyclol. Hepatol. Int. 2012;6(2):441–448.
13. Zeuzem S., Andreone P., Pol S. et al. Telaprevir for retreatment of HCV infection N. Engl. J. Med. 2011;364:2417–2428.
14. Zhao J., Chen H., Li Y. Protective effect of bicyclol on acutealcohol-induced liver injury in mice. Eur. J. Pharmacol. 2008;586(1–3):322–331.
Keywords: chronic hepatitis C, pathogenetic therapy, bicyclol